Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and operating results for the second quarter and ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

The US FDA has granted approval to Nyxoah’s Genio system for treating individuals with moderate to severe obstructive sleep ...

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.